() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: PreveCeutical Medical Inc

PreveCeutical Grants Asterion Option to Purchase up to a 51% Interest in Sol-Gel Intellectual Property

August 6, 2019 PreveCeutical Medical Inc. (“PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), and Asterion Cannabis Inc. (“Asterion”) announce that they have entered into an option to purchase agreement (the “Option Agreement”), whereby PreveCeutical has granted to Asterion the right and option (the“Option”) to purchase up to 51% of PreveCeutical’s right, title and interest in and to certain intellectual property rights relating to a soluble gel (“Sol-Gel”) nasal delivery system for the nose-to-brain delivery of therapeutic formulations, including cannabis and cannabinoids (the “Sol-Gel IP”).
Read more

PreveCeutical Successfully Incorporates Medicinal Cannabis Extracts into the Sol-Gel Drug Delivery System

July 9, 2019 PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces that it has completed the second phase of its soluble gel (“Sol-gel”) drug delivery research and development program (the “Sol-gel Program”), by successfully developing formulations for cannabis extract-infused Sol-gels (the “CBD Sol-gel Formulations”), where both the acid and neutral cannabis extract forms have been incorporated.
Read more

PreveCeutical Secures $300,000 Loan and Resignation of a Director

June 3, 2019, Vancouver, British Columbia: PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces that it has received a loan in the aggregate amount of $300,000 (the “Loan”) pursuant to a loan agreement with the Company’s Chairman and Chief Executive Officer, Mr. Stephen Van Deventer (the “Lender”).
Read more
Get $50 in free trades.